学习资源
科普文章
构型Format的重要性:几何结构定义了双特异性抗体的功能(一) [1]
1
背景:不同应用,不同format
重组蛋白和抗体工程的技术创新衍生了许多不同的抗体format。根据文献,很难找到普适于所有应用场景的“万能”format。合适的抗体构型取决于所需的生物学效应及其潜在的结构条件。多特异性抗体可用于各种目的,包括 (1) 受体激活、(2) 受体阻断、(3) 受体内化、(4) 受体集聚、(5) 关联膜相关蛋白,或 (6) 细胞毒性效应细胞的重定向(图 1)。在这些应用场景中,有几个例子证明format会影响双特异性抗体 (bsAb) 的性能。
参考文献
1.Dickopf, S., G.J. Georges, and U. Brinkmann, Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies. Computational and Structural Biotechnology Journal, 2020. 18: p. 1221-1227.
2.Shi, S.Y., et al., A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity. Journal of Biological Chemistry, 2018. 293(16): p. 5909-5919.
3.Ljungars, A., et al., A bispecific IgG format containing four independent antigen binding sites. Sci Rep, 2020. 10(1): p. 1546.
4.Milutinovic, S., et al., Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death. Mol Cancer Ther, 2016. 15(1): p. 114-24.
5.Kedage, V., et al., Harnessing MerTK agonism for targeted therapeutics. MAbs, 2020. 12(1): p. 1685832.
6.Woo, S.R., et al., Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res, 2012. 72(4): p. 917-27.
7.LaMotte-Mohs, R., et al., Abstract 3217: MGD013, a bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART®) protein with T-cell immunomodulatory activity for cancer treatment. Cancer Research, 2016. 76(14_Supplement): p. 3217-3217.
8.Jin, J., et al., An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations. Exp Mol Med, 2018. 50(5): p. 1-14.
9.Fan, Z., et al., Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. Journal of Biological Chemistry, 1994. 269(44): p. 27595-27602.
10.Niewoehner, J., et al., Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle. Neuron, 2014. 81(1): p. 49-60.
11.Weber, F., et al., Brain Shuttle Antibody for Alzheimer’s Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode. Cell Reports, 2018. 22(1): p. 149-162.
12.Yang, Y., et al., Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members. mAbs, 2019. 11(6): p. 996-1011.
13.Brünker, P., et al., RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis. Mol Cancer Ther, 2016. 15(5): p. 946-57.
14.Bargou, R., et al., Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody. Science, 2008. 321(5891): p. 974-977.
15.Lenting, P.J., C.V. Denis, and O.D. Christophe, Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood, 2017. 130(23): p. 2463-2468.
16.Kitazawa, T., et al., A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med, 2012. 18(10): p. 1570-4.
17.Labrijn, A.F., et al., Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov, 2019. 18(8): p. 585-608.